Tag: CAPTEM

clincial trials logo

Phase II Clinical Trial Recruiting Carcinoid and Related Neuroendocrine Tumor Patients

July 21, 2011

Participants are being recruited for a Phase II clinical study of capecitabine and temozolomide (CAPTEM) for neuroendocrine cancer patients with progressive, differentiated, metastatic neuroendocrine tumors (NETs). Patients with carcinoid,

READ MORE